Abstract
Rationale
When acutely administered intraperitoneally, the non-psychoactive cannabinoid cannabidiol (CBD), its acidic precursor cannabidiolic acid (CBDA) and a stable methyl ester of CBDA (HU-580) reduce lithium chloride (LiCl)–induced conditioned gaping in male rats (a selective preclinical model of acute nausea) via activation of the serotonin 1A (5-HT1A) receptor.
Objectives
To utilise these compounds to manage nausea in the clinic, we must determine if their effectiveness is maintained when injected subcutaneously (s.c) and when repeatedly administered. First, we compared the effectiveness of each of these compounds to reduce conditioned gaping following repeated (7-day) and acute (1-day) pretreatments and whether these anti-nausea effects were mediated by the 5-HT1A receptor. Next, we assessed whether the effectiveness of these compounds can be maintained when administered prior to each of 4 conditioning trials (once per week). We also evaluated the ability of repeated CBD (7 days) to reduce LiCl-induced vomiting in Suncus murinus. Finally, we examined whether acute CBD was equally effective in male and female rats.
Results
Both acute and repeated (7 day) s.c. administrations of CBD (5 mg/kg), CBDA (1 μg/kg) and HU-580 (1 μg/kg) similarly reduced LiCl-induced conditioned gaping, and these effects were blocked by 5HT1A receptor antagonism. When administered over 4 weekly conditioning trials, the anti-nausea effectiveness of each of these compounds was also maintained. Repeated CBD (5 mg/kg, s.c.) maintained its anti-emetic efficacy in S. murinus. Acute CBD (5 and 20 mg/kg, s.c.) administration reduced LiCl-induced conditioned gaping similarly in male and female rats.
Conclusion
When administered repeatedly (7 days), CBD, CBDA and HU-580 did not lose efficacy in reducing nausea and continued to act via agonism of the 5-HT1A receptor. When administered across 4 weekly conditioning trials, they maintained their effectiveness in reducing LiCl-induced nausea. Repeated CBD also reduced vomiting in shrews. Finally, CBD’s anti-nausea effects were similar in male and female rats. This suggests that these cannabinoids may be useful anti-nausea and anti-emetic treatments for chronic conditions, without the development of tolerance.
This is a preview of subscription content, access via your institution.
Abbreviations
- 5-HT1A :
-
Serotonin 1A
- ANOVA :
-
Analysis of variance
- CBD :
-
Cannabidiol
- CBDA :
-
Cannabidiolic acid
- CTA:
-
Conditioned taste avoidance
- DRN :
-
Dorsal raphe nucleus
- IIC :
-
Interceptive insular cortex
- i.p. :
-
Intraperitoneal
- LiCl :
-
Lithium chloride
- SAL :
-
Saline
- s.c. :
-
Subcutaneous
- TR :
-
Taste reactivity
- VEH :
-
Vehicle
- WAY :
-
WAY100635
References
Anderson LL, Low IK, Banister SD, McGregor IS, Arnold JC (2019) Pharmacokinetics of phytocannabinoid acids and anticonvulsant effect of cannabidiolic acid in a mouse model of Dravet syndrome. J Nat Prod 82:3047–3055. https://doi.org/10.1021/acs.jnatprod.9b00600
Araz M, Karaagac M, Korkmaz L, Koral L, Inci F, Beypinar I, Uysal M, Artac M (2019) Comparison of palonosetron and granisetron in triplet antiemetic therapy in nonmetastatic breast cancer patients receiving high emetogenic chemotherapy: a multicenter, prospective, and observational study. Cancer Chemother Pharmacol 83:1091–1097. https://doi.org/10.1007/s00280-019-03831-4
Bolognini D, Rock EM, Cluny NL, Cascio MG, Limebeer CL, Duncan M, Stott CG, Javid FA, Parker LA, Pertwee RG (2013) Cannabidiolic acid prevents vomiting in Suncus murinus and nausea-induced behaviour in rats by enhancing 5-HT1A receptor activation. Br J Pharmacol 168:1456–1470. https://doi.org/10.1111/bph.12043
Campos AC, de Paula SV, Carvalho MC, Ferreira FR, Vicente MA, Brandão ML, Zuardi AW, Zangrossi H Jr, Guimarães FS (2013) Involvement of serotonin-mediated neurotransmission in the dorsal periaqueductal gray matter on cannabidiol chronic effects in panic-like responses in rats. Psychopharmacology 226:13–24. https://doi.org/10.1007/s00213-012-2878-7
Campos AC, Fogaça MV, Sonego AB, Guimarães FS (2016) Cannabidiol, neuroprotection and neuropsychiatric disorders. Pharmacol Res 112:119–127. https://doi.org/10.1016/j.phrs.2016.01.033
Chow R, Tsao M, Chiu L, Popovic M, Milakovic M, Lam H, DeAngelis C (2018) Efficacy of the combination neurokinin-1 receptor antagonist, palonosetron, and dexamethasone compared to others for the prophylaxis of chemotherapy-induced nausea and vomiting: a systematic review and meta-analysis of randomized controlled trials. Ann Palliat Med 7:221–233. https://doi.org/10.21037/apm.2018.03.09
Clemmons AB, Orr J, Andrick B, Gandhi A, Sportes C, DeRemer D (2018) Randomized, placebo-controlled, phase III trial of fosaprepitant, ondansetron, dexamethasone (FOND) versus FOND plus olanzapine (FOND-O) for the prevention of chemotherapy-induced nausea and vomiting in patients with hematologic malignancies receiving highly emetogenic chemotherapy and hematopoietic cell transplantation regimens: the FOND-O trial. Biol Blood Marrow Transplant 24:2065–2071. https://doi.org/10.1016/j.bbmt.2018.06.005
Crombie L, Crombie WML (1977) Cannabinoid acids and esters: miniaturized synthesis and chromatographic study. Phytochemistry 16:1413–1420. https://doi.org/10.1016/S0031-9422(00)88794-4
De Gregorio D, McLaughlin RJ, Posa L, Ochoa-Sanchez R, Enns J, Lopez-Canul M, Aboud M, Maione S, Comai S, Gobbi G (2019) Cannabidiol modulates serotonergic transmission and reverses both allodynia and anxiety-like behavior in a model of neuropathic pain. Pain 160:136–150. https://doi.org/10.1097/j.pain.0000000000001386
Giagnuolo G, Buffardi S, Rossi F, Petruzziello F, Tortora C, Buffardi I, Marra N, Beneduce G, Menna G, Parasole R (2019) Single center experience on efficacy and safety of aprepitant for preventing chemotherapy-induced nausea and vomiting (CINV) in pediatric Hodgkin lymphoma. PLoS One 14:e0215295. https://doi.org/10.1371/journal.pone.0215295
Gralla RJ, Osoba D, Kris MG, Kirkbride P, Hesketh PJ, Chinnery LW, Clark-Snow R, Gill DP, Groshen S, Grunberg S, Koeller JM, Morrow GR, Perez EA, Silber JH, Pfister DG (1999) Recommendations for the use of antiemetics: evidence-based, clinical practice guidelines. J Clin Oncol 17:2971–2994. https://doi.org/10.1200/JCO.1999.17.9.2971
Grill HJ, Norgren R (1978) The taste reactivity test. I. Mimetic responses to gustatory stimuli in neurologically normal rats. Brain Res 43:263–279. https://doi.org/10.1016/0006-8993(78)90568-1
Guimarães FS, Chiaretti TM, Graeff FG, Zuardi AW (1990) Antianxiety effect of cannabidiol in the elevated plus-maze. Psychopharmacology 100:558–559. https://doi.org/10.1007/BF02244012
Hempel BJ, Clasen MM, Nelson KH, Woloshchuk CJ, Riley AL (2018) An assessment of concurrent cannabidiol and Δ9-tetrahydrocannabinol administration in place aversion and taste avoidance conditioning. Exp Clin Psychopharmacol 26:205–213. https://doi.org/10.1037/pha0000188
Hind WH, England TJ, O’Sullivan SE (2016) Cannabidiol protects an in vitro model of the blood-brain barrier from oxygen-glucose deprivation via PPARγ and 5-HT1A receptors. Br J Pharmacol 173:815–825. https://doi.org/10.1111/bph.13368
Ho C, MacDougall D (2019) Nabilone for the treatment of nausea and vomiting or anorexia: a review of clinical effectiveness and guidelines. Canadian Agency for Drugs and Technologies in Health, Ottawa
Javadi-Paydar M, Nguyen JD, Kerr TM, Grant Y, Vandewater SA, Cole M, Taffe MA (2018) Effects of Δ9-THC and cannabidiol vapor inhalation in male and female rats. Psychopharmacology 235:2541–2557. https://doi.org/10.1007/s00213-018-4946-0
Jesus CHA, Redivo DDB, Gasparin AT, Sotomaior BB, de Carvalho MC, Genaro K, Zuardi AW, Hallak JEC, Crippa JA, Zanoveli JM, da Cunha JM (2019) Cannabidiol attenuates mechanical allodynia in streptozotocin-induced diabetic rats via serotonergic system activation through 5-HT1A receptors. Brain Res 1715:156–164. https://doi.org/10.1016/j.brainres.2019.03.014
Kasten CR, Zhang Y, Boehm SL 2nd (2019) Acute cannabinoids produce robust anxiety-like and locomotor effects in mice, but long-term consequences are age- and sex-dependent. Front Behav Neurosci 13:32. https://doi.org/10.3389/fnbeh.2019.00032
King KM, Myers AM, Soroka-Monzo AJ, Tuma RF, Tallarida RJ, Walker EA, Ward SJ (2017) Single and combined effects of Δ(9) -tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain. Br J Pharmacol 174:2832–2841. https://doi.org/10.1111/bph.13887
Liaw CC, Wang CH, Chang HK, Liau CT, Yeh KY, Huang JS, Lin YC (2001) Gender discrepancy observed between chemotherapy-induced emesis and hiccups. Support Care Cancer 9:435–441. https://doi.org/10.1007/s005200000231
Limebeer CL, Vemuri VK, Bedard H, Lang ST, Ossenkopp KP, Makriyannis A, Parker LA (2010) Inverse agonism of cannabinoid CB1 receptors potentiates LiCl-induced nausea in the conditioned gaping model in rats. Br J Pharmacol 161:336–349. https://doi.org/10.1111/j.1476-5381.2010.00885.x
Limebeer CL, Rock EM, Sharkey KA, Parker LA (2018) Nausea-induced 5-HT release in the interoceptive insular cortex and regulation by monoacylglycerol lipase (MAGL) inhibition and cannabidiol. eNeuro 5:ENEURO.0256-18.2018. https://doi.org/10.1523/ENEURO.0256-18.2018
Linge R, Jiménez-Sánchez L, Campa L, Pilar-Cuéllar F, Vidal R, Pazos A, Adell A, Díaz Á (2016) Cannabidiol induces rapid-acting antidepressant-like effects and enhances cortical 5-HT/glutamate neurotransmission: role of 5-HT1A receptors. Neuropharmacology 103:16–26. https://doi.org/10.1016/j.neuropharm.2015.12.017
Long LE, Chesworth R, Huang XF, McGregor IS, Arnold JC, Karl T (2010) A behavioural comparison of acute and chronic delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. Int J Neuropsychopharmacol 13:861–876. https://doi.org/10.1017/s1461145709990605
Miller S, Daily L, Leishman E, Bradshaw H, Straiker A (2018) Δ9-Tetrahydrocannabinol and cannabidiol differentially regulate intraocular pressure. Invest Ophthalmol Vis Sci 59:5904–5911. https://doi.org/10.1167/iovs.18-24838
Navari RM, Rapoport BL, Powers D, Arora S, Clark-Snow R (2018) Rolapitant for the prevention of nausea in patients receiving highly or moderately emetogenic chemotherapy. Cancer Med 7:2943–2950. https://doi.org/10.1002/cam4.1560
Parker LA (2014) Conditioned flavor avoidance and conditioned gaping: rat models of conditioned nausea. Eur J Pharmacol 722:122–133. https://doi.org/10.1016/j.ejphar.2013.09.070
Parker LA, Mechoulam R (2003) Cannabinoid agonists and antagonists modulate lithium-induced conditioned gaping in rats. Integr Physiol Behav 38:133–145. https://doi.org/10.1007/BF02688831
Parker LA, Kwiatkowska M, Burton P, Mechoulam R (2004) Effect of cannabinoids on lithium-induced vomiting in the Suncus murinus (house musk shrew). Psychopharmacology 171:156–161. https://doi.org/10.1007/s00213-003-1571-2
Pertwee RG, Rock EM, Guenther K, Limebeer CL, Stevenson LA, Haj C, Smoum R, Parker LA, Mechoulam R (2018) Cannabidiolic acid methyl ester, a stable synthetic analogue of cannabidiolic acid, can produce 5-HT1A receptor-mediated suppression of nausea and anxiety in rats. Br J Pharmacol 175:100–112. https://doi.org/10.1111/bph.14073
Peyron C, Petit JM, Rampon C, Jouvet M, Luppi PH (1998) Forebrain afferents to the rat dorsal raphe nucleus demonstrated by retrograde and anterograde tracing methods. Neuroscience 82:443–468. https://doi.org/10.1016/s0306-4522(97)00268-6
Rock EM, Parker LA (2013) Effect of low doses of cannabidiolic acid and ondansetron on LiCl-induced conditioned gaping (a model of nausea-induced behaviour) in rats. Br J Pharmacol 169:685–692. https://doi.org/10.1111/bph.12162
Rock EM, Parker LA (2016) Cannabinoids as potential treatment for chemotherapy-induced nausea and vomiting. Front Pharmacol 7:221. https://doi.org/10.3389/fphar.2016.00221
Rock EM, Goodwin JM, Limebeer CL, Breuer A, Pertwee RG, Mechoulam R, Parker LA (2011) Interaction between non-psychotropic cannabinoids in marihuana: effect of cannabigerol (CBG) on the anti-nausea or anti-emetic effects of cannabidiol (CBD) in rats and shrews. Psychopharmacology 215:505–512. https://doi.org/10.1007/s00213-010-2157-4
Rock EM, Bolognini D, Limebeer CL, Cascio MG, Anavi-Goffer S, Fletcher PJ, Mechoulam R, Pertwee RG, Parker LA (2012) Cannabidiol, a non-psychotropic component of cannabis, attenuates vomiting and nausea-like behaviour via indirect agonism of 5-HT(1A) somatodendritic autoreceptors in the dorsal raphe nucleus. Br J Pharmacol 165:2620–2634. https://doi.org/10.1111/j.1476-5381.2011.01621.x
Rock EM, Kopstick RL, Limebeer CL, Parker LA (2013) Tetrahydrocannabinolic acid reduces nausea-induced conditioned gaping in rats and vomiting in Suncus murinus. Br J Pharmacol 170:641–648. https://doi.org/10.1111/bph.12316
Rock EM, Limebeer CL, Parker LA (2015) Effect of combined doses of Δ(9)-tetrahydrocannabinol (THC) and cannabidiolic acid (CBDA) on acute and anticipatory nausea using rat (Sprague- Dawley) models of conditioned gaping. Psychopharmacol (Berl) 232:4445–4454. https://doi.org/10.1007/s00213-015-4080-1
Rock EM, Limebeer CL, Petrie GN, Williams LA, Mechoulam R, Parker LA (2017) Effect of prior foot shock stress and Δ9-tetrahydrocannabinol, cannabidiolic acid, and cannabidiol on anxiety-like responding in the light-dark emergence test in rats. Psychopharmacology 234:2207–2217. https://doi.org/10.1007/s00213-017-4626-5
Rock EM, Sullivan MT, Pravato S, Pratt M, Limebeer CL, Parker LA (2020) Effect of combined doses of Δ9-tetrahydrocannabinol and cannabidiol or tetrahydrocannabinolic acid and cannabidiolic acid on acute nausea in male Sprague-Dawley rats. Psychopharmacology 237:901–914. https://doi.org/10.1007/s00213-019-05428-4
Sepúlveda-Vildósola AC, Betanzos-Cabrera Y, Lastiri GG, Rivera-Márquez H, Villasis-Keever MA, Del Angel VW, Díaz FC, López-Aguilar E (2008) Palonosetron hydrochloride is an effective and safe option to prevent chemotherapy-induced nausea and vomiting in children. Arch Med Res 39:601–606. https://doi.org/10.1016/j.arcmed.2008.04.007
Sotelo C, Cholley B, El Mestikawy S, Gozlan H, Hamon M (1990) Direct immunohistochemical evidence of the existence of 5-HT1A autoreceptors on serotoninergic neurons in the midbrain raphe nuclei. Eur J Neurosci 2:1144–1154. https://doi.org/10.1111/j.1460-9568.1990.tb00026.x
Timaeus S, Elder J, Franco K (2018) Evaluation of the use of fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting in pediatric patients. J Pediatr Hematol Oncol 40:527–531. https://doi.org/10.1097/MPH.0000000000001213
Tsuji D, Suzuki K, Kawasaki Y, Goto K, Matsui R, Seki N, Hashimoto H, Hama T, Yamanaka T, Yamamoto N, Itoh K (2019) Risk factors associated with chemotherapy-induced nausea and vomiting in the triplet antiemetic regimen including palonosetron or granisetron for cisplatin-based chemotherapy: analysis of a randomized, double-blind controlled trial. Support Care Cancer 27:1139–1147. https://doi.org/10.1007/s00520-018-4403-y
Verge D, Daval G, Patey A, Gozlan H, el Mestikawy S, Hamon M (1985) Presynaptic 5-HT autoreceptors on serotonergic cell bodies and/or dendrites but not terminals are of the 5-HT1A subtype. Eur J Pharmacol 113:463–464. https://doi.org/10.1016/0014-2999(85)90099-8
Vertes RP (1991) A PHA-L analysis of ascending projections of the dorsal raphe nucleus in the rat. J Comp Neurol 313:643–668. https://doi.org/10.1002/cne.903130409
Zhu YF, Linher-Melville K, Niazmand MJ, Sharma M, Shahid A, Zhu KL, Parzei N, Sidhu J, Haj C, Mechoulam R, Singh G (2020) An evaluation of the anti-hyperalgesic effects of cannabidiolic acid-methyl ester (CBDA-ME) in a preclinical model of peripheral neuropathic pain. Br J Pharmacol 177:2712–2725. https://doi.org/10.1111/bph.14997
Funding
The research described here was funded by research grants from the Natural Sciences and Engineering Council of Canada (NSERC: 03629) and Canadian Institutes of Health Research (CIHR: 388239).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflicts of interest.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Rock, E.M., Sullivan, M.T., Collins, S.A. et al. Evaluation of repeated or acute treatment with cannabidiol (CBD), cannabidiolic acid (CBDA) or CBDA methyl ester (HU-580) on nausea and/or vomiting in rats and shrews. Psychopharmacology 237, 2621–2631 (2020). https://doi.org/10.1007/s00213-020-05559-z
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00213-020-05559-z